FWK Holdings LLC et al v. Takeda Pharmaceutical Company Ltd. et al
Case Number:
1:21-cv-11057
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Dechert LLP
- Getnick Law
- Hagens Berman
- Hangley Aronchick
- Haug Partners
- Lowey Dannenberg
- NastLaw
- Radice Law Firm
- Sperling Kenny
- Tucker Dyer
- Wilson Sonsini
Companies
- Albertsons Cos. Inc.
- CVS Health Corp.
- Endo International PLC
- Par Pharmaceutical Cos. Inc.
- Premera Blue Cross
- Takeda Pharmaceutical Co. Ltd.
- The Kroger Co.
Sectors & Industries:
-
March 20, 2025
Judge Won't Let Meijer Appeal Takeda's Arbitration Mandate
A Massachusetts federal judge refused Thursday to let Meijer immediately appeal his order letting Takeda Pharmaceutical force the grocery chain into arbitration and out of its role as a representative of a proposed class of direct purchasers suing over delayed generics to a constipation drug.
-
March 04, 2025
Meijer Says 1st Circ. Must Resolve Takeda Arbitration Order
Grocery store chain Meijer on Tuesday urged a Massachusetts federal judge to allow it to immediately appeal his ruling granting Takeda Pharmaceutical's bid to arbitrate the grocer's antitrust claims over a constipation drug, arguing that the case presents several issues that the First Circuit needs to address.
-
January 27, 2025
Takeda Pushes Meijer Antitrust Suit Into Arbitration
Meijer is going to have to arbitrate its claims that Takeda Pharmaceutical broke antitrust law by cutting a pay-for-delay deal with Par Pharmaceuticals to keep a generic version of Takeda's anti-constipation drug Amitiza off the market for several years.
-
July 10, 2024
Meijer Says Takeda Can't Force Antitrust Suit Into Arbitration
Meijer argued before a Massachusetts federal court that Takeda waited far too long to try to force the supermarket chain to arbitrate its proposed class action accusing the Japanese pharmaceutical company of conspiring to delay a generic version of its anti-constipation drug Amitiza.
-
January 23, 2023
Court Consolidates Takeda Antitrust Suits Over IBS Drug
A Massachusetts federal judge on Monday consolidated a pair of proposed class actions alleging that Takeda Pharmaceutical broke antitrust law by cutting a pay-for-delay deal to keep a generic version of its anti-constipation drug Amitiza off the market for over six years.
-
June 28, 2021
Takeda Hit With Antitrust Suit Over IBS Drug Amitiza
Takeda Pharmaceutical broke antitrust law when it cut a pay-for-delay deal with Par Pharmaceuticals to keep a generic version of Takeda's anti-constipation drug Amitiza off the market for more than six years, according to a proposed class action in Massachusetts federal court.